An open-label global study of oral SCY-078 for patients suffering from infections caused by Candida auris

Trial Profile

An open-label global study of oral SCY-078 for patients suffering from infections caused by Candida auris

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2017

At a glance

  • Drugs SCY 078 (Primary)
  • Indications Candidiasis
  • Focus Therapeutic Use
  • Acronyms CARES
  • Most Recent Events

    • 15 Nov 2017 New trial record
    • 07 Nov 2017 According to a SCYNEXIS media release, patient enrollment is expected to commence in the fourth quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top